Using contrast-enhanced ultrasound to diagnose recurrent kidney cancer after treatment
Multi-Modality Detection of RCC Recurrence Post Ablation
This study is testing if a special type of ultrasound can better detect kidney cancer that comes back after treatment compared to regular imaging methods like CT and MRI.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 210 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Thomas Jefferson University Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT05641935 on ClinicalTrials.gov |
What this trial studies
This phase II trial investigates the effectiveness of contrast-enhanced ultrasound (CEUS) in diagnosing recurrent renal cell carcinoma (RCC) following ablation treatments. The study aims to compare the diagnostic accuracy of CEUS with traditional imaging methods like CT and MRI by evaluating sensitivity, specificity, and predictive values. Additionally, it explores the potential benefits of combining CEUS with pre-treatment imaging and utilizing advanced imaging techniques to enhance detection capabilities. Patients will receive Lumason for CEUS imaging and have their medical records reviewed regularly throughout the study.
Who should consider this trial
Good fit: Ideal candidates include adults who have previously undergone cryotherapy or microwave therapy for renal cell carcinoma and have available pre-treatment imaging.
Not a fit: Patients who are medically unstable, terminally ill, or have known sensitivities to the study's contrast agent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more accurate and less invasive method for monitoring kidney cancer recurrence, improving patient outcomes.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in enhancing imaging techniques for cancer detection, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Previously received cryotherapy or microwave therapy of RCC * Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy * Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study * Be at least 18 years of age * Be medically stable * If a female of child-bearing age, must have a negative pregnancy test * Have signed Informed Consent to participate in the study Exclusion Criteria: * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable * Patients with known sensitivities to the components of Lumason
Where this trial is running
Philadelphia, Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: John Eisenbrey, PhD
- Email: john.eisenbrey@jefferson.edu
- Phone: 215-503-5188
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.